Abstract The purpose was to review the pharmacology, safety, and efficacy of bezlotoxumab (Zinplava; Merck Sharp & Dohme Corp, Whitehouse Station, NJ) as a novel therapy for prevention of recurrent Clostridium difficile infection (CDI). MEDLINE was searched (1946 to February 2017) using the terms bezlotoxumab, MK6072, MBL-CDB1, and MDX-1388. Additional studies were identified through searching FDA.gov, clinicaltrials.gov, and review of reference lists. Studies included were randomized control trials in English language on bezlotoxumab for recurrent CDI. Animal studies were excluded. Three randomized control trials were identified evaluating bezlotoxumab in adults receiving standard of care therapy for CDI. The primary outcome evaluated in all trials was CDI recurrence. A phase II trial found the combination of bezlotoxumab-actoxumab compared with placebo decreased CDI recurrence at 84 days (7% vs 25%, P < 0.001). Two similar, yet independent phase III trials evaluated recurrent CDI at 12 weeks. Results were consistent between the 2 trials and pooled analysis displayed a reduction in CDI recurrence in the bezlotoxumab group (absolute difference, −10.1%; 95% confidence interval, −14 to −6; P < 0.001) and the bezlotoxumab-actoxumab group (absolute difference, −11.5%; 95% confidence interval, −15.2 to −7.2; P < 0.001) compared with placebo. Initial and sustained clinical cure rates were similar between bezlotoxumab, bezlotoxumab-actoxumab, and placebo. Overall, the adverse effects associated with bezlotoxumab were similar to placebo, with diarrhea, nausea, pyrexia, and headache having a higher occurrence than placebo. In conclusion, bezlotoxumab is safe and effective at reducing CDI recurrence and the use of bezlotoxumab should be considered in patients who are at highest risk for CDI.
Infectious Diseases in Clinical Practice – Wolters Kluwer Health
Published: Apr 1, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera